摘要
目的研究高三尖杉酯碱(homoharingtonine,HHT)脂质体及高三尖杉酯碱注射液对兔滤过术后抗瘢痕形成的疗效及毒性。方法对40只家兔双眼行巩膜后唇咬切术,自术后次日起,第1组结膜下注射HHT脂质体,第2组结膜下注射空白脂质体(对照组),第3组结膜下注射低剂量HHT注射液,第4组结膜下注射生理盐水(对照组),第5组结膜下注射高剂量HHT注射液。结果2个对照组的滤过泡在术后7天失败,低剂量HHT组的滤过泡在术后9天失败,HHT脂质体组的滤过泡在术后12天失败,高剂量HHT组的滤过泡在术后15天失败。术后5~10天,高剂量HHT组的巩膜瘘道阻塞率为375%,其余4组的阻塞率均为1000%;术后15~30天,5组的巩膜瘘道阻塞率均为1000%。高剂量HHT组中630%的眼出现中至重度角膜水肿及角膜血管翳。结论对兔眼滤过术后应用HHT脂质体和低剂量HHT注射液不能明显提高兔眼滤过术的成功率。应用高剂量HHT注射液可暂时提高兔眼滤过术的成功率,但副作用亦明显增加。
Objective Homoharringtonine (HHT), a Chinese herbal drug, was used in the form of liposome or solution as an adjunct to glaucoma filtration surgery in rabbits to determine its effect in preventing closure of sclerostomy. Methods Forty rabbits that underwent a standard posterior lip sclerectomy in both eyes were divided into 5 post operative groups. Group 1 received subconjunctival HHT liposomes (0.025%). Group 2 received subconjunctival blank liposomes and served as control. Group 3 and 5 received subconjunctival HHT solution at low (0.025%)and high (0.1%) doses respectively. Group 4 received subconjunctival normal saline and served as control. Intraocular pressure, interval between operation and bleb failure, rate of scleral fistula occlusion and ocular toxicity were determined in each group. Results Subconjunctival treatment with HHT solution at a high dose transiently prolongs the survival of filtration surgery, but the subconjunctival use with HHT liposomes or HHT solution at a low dose does not significantly prolong the survival of filtration surgery in rabbits. Significant corneal haze and corneal neovascularization resulted from using HHT at a high dose. Conclusions The success rate of rabbit filtration surgery can not be markedly increased by the postoperative use of HHT liposomes or its low dose solution. When the high dosage of HHT solution is used, transient elevation of the success rate can be obtained, however the side effect is also significantly increased.
出处
《中华眼科杂志》
CAS
CSCD
北大核心
1998年第4期304-307,I021,共5页
Chinese Journal of Ophthalmology
关键词
高三尖杉酯碱
脂质体
青光眼
滤过术
Homoharringtonine Liposomes Glaucoma Filtering surgery